PMID- 23597930
OWN - NLM
STAT- MEDLINE
DCOM- 20140121
LR  - 20220408
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 81
IP  - 1
DP  - 2013 Jul
TI  - Diagnosis of recurrence and assessment of post-recurrence survival in patients 
      with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
PG  - 71-6
LID - S0169-5002(13)00120-7 [pii]
LID - 10.1016/j.lungcan.2013.03.015 [doi]
AB  - The accurate diagnosis of recurrence of non small cell lung cancer (NSCLC) is 
      crucial for the appropriate management of patients with suspicion of recurrence 
      (SOR). We evaluated prospectively in the clinical setting the contribution of FDG 
      PET/CT in patients with SOR of NSCLC in terms of sensitivity, specificity, impact 
      on therapy and on survival. METHODS: Of the 55 patients included in the study, 
      recurrence was confirmed in 37 but, follow up data for survival evaluation was 
      available in 34. There were 59 SOR in the 55 patients and in 41 recurrence was 
      confirmed. 53 of the 59 suspicions, had a contrast enhanced CT. All patients had 
      a FDG PET/CT scan after iv injection of 8 MBq/kg of F18-FDG. RESULTS: Of the 59 
      SOR, FDG PET/CT was positive in all 41 in which recurrence was confirmed (100% 
      sensitivity) and, it was negative in 15 of the 18 in which it was ruled out 
      (specificity 83%). In 27 SOR with inconclusive CT, FDG PET/CT showed 100% 
      sensitivity (18/18) and 78% specificity (7/9). FDG PET/CT had an impact on 
      treatment in 42 of the 59 SOR. In all 34 patients, FDG PET/CT diagnosed 
      recurrence and overall survival at 20 months and 5 years was 44% and 11%, 
      respectively. When the extent of recurrence assessed by FDG PET/CT was 
      considered, survival at 20 months and at 5 years of patients with loco-regional 
      recurrence was 77% and 28% and in patients with distant recurrence 14% and 0% (p 
      < 0.001). CONCLUSION: Despite the small number of patients, our study 
      demonstrates that FDG PET/CT is highly accurate for the detection of NSCLC 
      recurrence. Therefore it has a great impact on the therapy regimen and on 
      survival depending on the extent of the recurrent disease, survival being better 
      for patients with local recurrence. By differentiating local from distant 
      recurrence, it allows the selection of patients who, could potentially benefit 
      from new therapies. The results also suggest that there are grounds to include 
      FDG PET/CT in the guidelines for surveillance for NSCLC.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Jimenez-Bonilla, Julio F
AU  - Jimenez-Bonilla JF
AD  - Nuclear Medicine Department, University Hospital, Marques de Valdecilla, 
      University of Cantabria, Santander, Spain. jjimenez@humv.es
FAU - Quirce, Remedios
AU  - Quirce R
FAU - Martinez-Rodriguez, Isabel
AU  - Martinez-Rodriguez I
FAU - Banzo, Ignacio
AU  - Banzo I
FAU - Rubio-Vassallo, Adriana S
AU  - Rubio-Vassallo AS
FAU - Del Castillo-Matos, Rosangie
AU  - Del Castillo-Matos R
FAU - Ortega-Nava, Fernando
AU  - Ortega-Nava F
FAU - Martinez-Amador, Nestor
AU  - Martinez-Amador N
FAU - Ibanez-Bravo, Susana
AU  - Ibanez-Bravo S
FAU - Carril, Jose M
AU  - Carril JM
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130415
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*diagnosis/mortality
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/*diagnosis/mortality
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*diagnosis/mortality
MH  - Positron-Emission Tomography/*methods
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Tomography, X-Ray Computed/*methods
EDAT- 2013/04/20 06:00
MHDA- 2014/01/22 06:00
CRDT- 2013/04/20 06:00
PHST- 2012/12/13 00:00 [received]
PHST- 2013/03/16 00:00 [accepted]
PHST- 2013/04/20 06:00 [entrez]
PHST- 2013/04/20 06:00 [pubmed]
PHST- 2014/01/22 06:00 [medline]
AID - S0169-5002(13)00120-7 [pii]
AID - 10.1016/j.lungcan.2013.03.015 [doi]
PST - ppublish
SO  - Lung Cancer. 2013 Jul;81(1):71-6. doi: 10.1016/j.lungcan.2013.03.015. Epub 2013 
      Apr 15.